PMVP

PMV Pharmaceuticals, Inc.

Healthcare
Biotechnology
$75M market cap

Forecast run · Sep 14, 2026Upside rank 195 of 3,136

Model Signal

ForecastQ Daily Probabilities

66.6%

55.2%

43.9%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$1.40

Price target$5.00

Implied move+257.1%

Analysts4

ForecastQ Portfolios

PMVP is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.